Cialis (Tadalafil) vs. Vardenafil (Levitra/Staxyn): Cost and Access Head-to-Head

How Generic Pricing Compares Right Now

Generic tadalafil is one of the most affordable PDE5 inhibitors on the US market. Since Eli Lilly's patent expired in September 2018, more than a dozen manufacturers have entered the generic tadalafil space, driving retail prices for a 20 mg tablet to as low as $0.30 at discount pharmacies and $0.50 to $2.00 at most chains [1]. Generic vardenafil, also available since 2018, has attracted fewer manufacturers. Retail prices for a 20 mg vardenafil tablet generally range from $1.00 to $4.00 depending on pharmacy and region [2].

The price gap widens with daily dosing. Tadalafil 5 mg daily (the dose approved for both ED and benign prostatic hyperplasia) often costs $15 to $45 per month through discount programs [1]. Vardenafil has no FDA-approved daily regimen, so men using it typically pay per-event, which can exceed $60 to $120 per month at 2 to 3 uses per week [2]. A 2019 analysis in the Journal of Sexual Medicine found that among generic PDE5 inhibitors, tadalafil had the lowest mean out-of-pocket cost per dose in US retail pharmacies [3].

Staxyn, the orally disintegrating formulation of vardenafil, remains brand-only. No generic ODT version is FDA-approved, and a single Staxyn 10 mg tablet can cost $30 to $50 [4]. For men who prefer an ODT format, this represents a significant cost barrier compared to swallowing a generic tadalafil tablet.

Insurance Coverage and Formulary Placement

Tadalafil holds a formulary advantage that vardenafil does not. The reason is straightforward: the FDA approved tadalafil 5 mg daily for BPH symptoms in 2011, giving it a medical (not purely lifestyle) indication [5]. Many commercial insurers and Medicare Part D plans cover tadalafil daily under the BPH indication even when they exclude ED drugs from their formulary [6].

Vardenafil lacks a BPH indication. It is classified strictly as an ED medication. Most Medicare Part D plans exclude lifestyle ED drugs entirely, and commercial plans that do cover ED medications frequently tier vardenafil at a higher copay than tadalafil [6]. According to a 2020 formulary analysis published in Urology Practice, tadalafil appeared on 68% of surveyed commercial formularies compared to 41% for vardenafil [7].

Prior authorization requirements also differ. Insurers covering tadalafil for BPH rarely require prior authorization, while those covering any PDE5 inhibitor for ED almost universally require a documented trial-and-failure or clinical justification letter [7]. Men with concurrent BPH and ED symptoms may find tadalafil daily the path of least bureaucratic resistance.

Clinical Efficacy: What the Trials Actually Show

Both drugs work. The clinical question is whether one works better enough to justify a higher price. No large, prospective, head-to-head randomized controlled trial directly compares tadalafil to vardenafil. The evidence comes from separate key trials and meta-analyses.

Brock et al. (2002) reported that tadalafil 20 mg improved the International Index of Erectile Function (IIEF) erectile function domain score by a mean of 7.9 points over placebo (N=348 in the 20 mg arm), with efficacy persisting up to 36 hours post-dose [8]. Porst et al. (2003) demonstrated that vardenafil 20 mg improved IIEF-EF scores by approximately 7.5 points over placebo in men with diabetes-related ED (N=280 in the 20 mg arm), confirming strong efficacy in a harder-to-treat population [9].

A 2013 Cochrane-style network meta-analysis published in European Urology pooled 82 RCTs (N=47,626) and found no statistically significant difference in IIEF-EF score improvement between tadalafil 20 mg and vardenafil 20 mg (mean difference 0.3 points, 95% CI: -0.9 to 1.5) [10]. The practical conclusion: on-demand efficacy is equivalent. The difference lies in pharmacokinetics, not pharmacodynamics.

Tadalafil's 17.5-hour half-life versus vardenafil's 4 to 5-hour half-life means tadalafil provides a wider window of efficacy [11]. For men who value spontaneity or dislike timing sex around a pill, that pharmacokinetic profile carries real-world weight. The American Urological Association (AUA) guideline on ED notes that patient preference for dosing flexibility is a valid reason to choose tadalafil over shorter-acting alternatives [12].

Daily Dosing: Tadalafil's Unique Advantage

Tadalafil is the only PDE5 inhibitor with FDA approval for continuous daily dosing at 2.5 mg or 5 mg [5]. This matters for cost modeling. A man taking tadalafil 5 mg daily pays a fixed monthly amount (often $15 to $45 with a discount card) regardless of sexual frequency. A man using vardenafil 20 mg on demand pays per encounter.

At 2 or fewer encounters per week, on-demand vardenafil may cost roughly the same as daily tadalafil. At 3 or more encounters per week, daily tadalafil becomes significantly cheaper. For men in stable relationships with regular sexual activity, the daily option often wins on both convenience and total monthly spend.

A 2017 analysis in The Journal of Urology found that daily tadalafil 5 mg produced IIEF-EF improvements comparable to on-demand tadalafil 20 mg after 12 weeks, with higher patient satisfaction scores for the daily arm (p=0.02) [13]. Vardenafil's labeling does not support daily use, and off-label daily vardenafil prescribing lacks the evidence base to support insurance reimbursement.

Beyond ED, daily tadalafil 5 mg reduces International Prostate Symptom Scores (IPSS) by a mean of 4.8 points versus 2.2 for placebo in men with BPH [14]. That dual indication means a single daily pill can address two conditions, a cost-efficiency vardenafil cannot replicate.

Access Pathways: Telehealth, Cash-Pay, and Pharmacy Programs

The telehealth ED market has expanded access for both medications, but tadalafil dominates the online pharmacy space. Platforms like HealthRX, Hims, Ro, and BlueChew primarily offer generic tadalafil and sildenafil. Generic vardenafil is available on some platforms but is less frequently featured because its higher per-tablet cost makes subscription pricing less attractive [15].

Cash-pay discount programs (GoodRx, RxSaver, manufacturer coupons) show a consistent gap. At the time of writing, GoodRx-listed prices for 30 tablets of generic tadalafil 20 mg average $15 to $40, while 30 tablets of generic vardenafil 20 mg average $35 to $90 at major chain pharmacies [3]. That 2x to 3x multiplier reflects the competitive dynamics of the generic market: more tadalafil manufacturers equals lower prices.

For men without insurance or with plans that exclude ED medications, the cash-pay gap makes tadalafil the default first choice on cost alone. The AUA recommends that clinicians discuss cost and access as part of shared decision-making when selecting a PDE5 inhibitor, since efficacy differences are minimal [12].

Mail-order pharmacies (Express Scripts, Optum Rx, Amazon Pharmacy) tend to offer the deepest discounts on high-volume generics. Tadalafil qualifies. Vardenafil's lower prescription volume means mail-order savings are less consistent [15].

Side Effect Profile and Tolerability Trade-Offs

Side effects influence long-term adherence, which in turn affects real-world cost-effectiveness. Both tadalafil and vardenafil share the class-wide PDE5 inhibitor side effects: headache, flushing, nasal congestion, and dyspepsia [5] [4]. Rates are similar across key trials. In Brock et al., headache occurred in 15% of the tadalafil 20 mg group versus 5% placebo [8]. In Porst et al., headache occurred in 16% of the vardenafil 20 mg group versus 4% placebo [9].

One clinically relevant difference: tadalafil causes back pain and myalgia in approximately 6% of users at the 20 mg dose, a side effect rare with vardenafil [16]. This is attributed to tadalafil's inhibition of PDE11, an isoenzyme expressed in skeletal muscle. Vardenafil is more selective for PDE5 and does not cause meaningful PDE11 inhibition [16].

Vardenafil carries a unique QTc prolongation warning. The FDA label notes a mean QTc increase of 8 ms at the 10 mg dose, and vardenafil is contraindicated in men taking Class IA or Class III antiarrhythmics [4]. Tadalafil does not prolong QTc at therapeutic doses [17]. For men with cardiac history or on rhythm-control medications, this distinction narrows the choice.

A man who tolerates one PDE5 inhibitor poorly can switch to another. The 2018 AUA guideline explicitly states that trial of an alternative PDE5 inhibitor is appropriate before concluding PDE5 inhibitor failure [12].

Who Should Choose Vardenafil Despite the Cost Premium

Vardenafil is not obsolete. Specific clinical scenarios favor it over tadalafil.

Men who develop back pain or myalgia on tadalafil may tolerate vardenafil without those effects [16]. Men who prefer a shorter duration of action (some report that tadalafil's 36-hour window causes prolonged flushing or nasal congestion) may find vardenafil's 4 to 6-hour window more comfortable [11]. Men with difficulty swallowing tablets can use Staxyn, the ODT formulation that dissolves on the tongue without water [4].

A 2007 study in BJU International found that among men who had previously failed sildenafil, 62% achieved successful intercourse when switched to vardenafil 20 mg [18]. This "PDE5 inhibitor rotation" strategy is well-established. If a man fails or has intolerable side effects on tadalafil, vardenafil is a reasonable and evidence-backed second-line PDE5 inhibitor.

The cost premium for vardenafil (roughly 2x to 3x per dose versus generic tadalafil) is modest in absolute terms. A man using vardenafil 8 times per month at $3 per tablet spends $24. That is clinically affordable for most patients, even without insurance coverage [3].

International Access and Pricing Differences

Outside the United States, pricing dynamics differ substantially. In the United Kingdom, both generic tadalafil and generic vardenafil are available over the counter from pharmacies after a clinical consultation, following the MHRA's 2018 reclassification of sildenafil and subsequent policy extensions [19]. Prices in UK pharmacies run £0.50 to £2.00 per tablet for either generic.

In Canada, both generics are prescription-only and covered variably by provincial formularies. Ontario's Drug Benefit Program lists tadalafil but not vardenafil for BPH, mirroring the US pattern of dual-indication coverage favoring tadalafil [20]. In Australia, tadalafil is listed on the Pharmaceutical Benefits Scheme for BPH at a patient copay of AUD $7.70 (concession) or $32.50 (general), while vardenafil is not PBS-listed [20].

The global pattern is consistent: tadalafil's BPH indication creates a reimbursement pathway that vardenafil, as an ED-only drug, cannot access.

Making the Decision: A Practical Framework

The clinical and economic data point in the same direction for most men. Generic tadalafil costs less per dose, offers daily and on-demand dosing flexibility, has broader insurance coverage through its BPH indication, and provides a 36-hour efficacy window. For men starting PDE5 inhibitor therapy without a specific contraindication to tadalafil, it is the rational first choice on cost and access grounds [12].

Vardenafil earns its place for men who develop myalgia on tadalafil, prefer a shorter duration of action, need an ODT formulation, or have already responded well to it [18]. Cost should not be the sole deciding factor when the monthly difference is $20 to $40. Tolerability and adherence matter more than per-tablet price if a cheaper drug sits unused in the medicine cabinet.

The AUA guideline recommends starting any PDE5 inhibitor at the lowest effective dose and titrating based on efficacy and side effects [12]. For tadalafil, that means 10 mg on-demand or 2.5 mg daily. For vardenafil, 10 mg on-demand. Prescribers should document the rationale for drug selection, especially when insurance prior authorization is anticipated.

Men filling their first PDE5 inhibitor prescription should ask their pharmacy to run both generic tadalafil and generic vardenafil through their insurance before committing. The copay difference alone often makes the decision. For cash-pay patients, generic tadalafil 20 mg split in half (a common off-label strategy yielding two 10 mg doses) can reduce per-dose cost below $0.25 [3].